New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting

Print

Date: 07/11/2019

ASCO Scientists
David Polsky, MD, PhD, of NYU Langone Medical Center; Jenny Lee, MD, of Macquarie University in Sydney and the Melanoma Institute Australia; and Ya-Chun Wang, PhD, of TCM Biotech International Corporation presented research at ASCO that showcases the role of Droplet Digital PCR in analyzing liquid biopsies.

HERCULES, Calif.  — Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4. Many of these studies used liquid biopsy powered by the ddPCR platform to measure circulating tumor DNA (ctDNA) and evaluate ctDNA’s potential as a biomarker for guiding cancer treatment decisions and predicting efficacy. 

Detecting and analyzing ctDNA in liquid biopsy samples is gaining recognition as a less invasive method of monitoring disease progression. Researchers are not only testing known mutations in various cancers but are also discovering new mutations that may become important biomarkers. However, wider clinical adoption requires that these ctDNA biomarkers be tested in various cancers and clinical conditions. The studies below highlight efforts to evaluate ctDNA as a potential biomarker vehicle to monitor treatment efficacy, tumor progression, or tumor recurrence.

Mutant BRAF ctDNA is a potential biomarker for advanced melanoma treatment efficacy

There are currently no validated blood-based biomarkers for monitoring treatment efficacy in patients with advanced melanoma. David Polsky, MD, PhD, of NYU Langone Medical Center, and his colleagues are one of the teams that are studying the potential of ctDNA as a biomarker for treatment efficacy in this disease.

The researchers examined ctDNA containing a mutated gene known as BRAF, which is commonly associated with melanoma, in 345 patients undergoing therapy. Using ddPCR technology, Polsky’s team was able to determine that baseline concentration of ctDNA with this mutation negatively correlated with patient survival. Additionally, Polsky found that patients survived longer when their levels of mutated BRAF ctDNA dropped to undetectable levels after four weeks of treatment.

“The reason we could conduct this quantitative analysis was because the ddPCR platform delivers highly accurate and precise measurements of the amount of mutated DNA in a sample,” said Polsky.

ctDNA may not reliably predict progression of melanoma metastases in the brain

Jenny Lee, MD, of Macquarie University in Sydney and the Melanoma Institute Australia, and her colleagues discovered the limitations of using ctDNA to analyze the progression of advanced melanoma when the cancer has metastasized specifically to the brain.

Following up on an earlier study, Lee and her colleagues used ddPCR technology to analyze ctDNA levels in 48 patients with advanced melanoma and brain metastases. All the patients were receiving immune checkpoint therapy. Eight had metastases in their brains but nowhere else. The researchers found that an absence of detectable tumor ctDNA at the start or at an early stage of treatment was a good sign. Specifically, it was associated with superior progression-free survival and overall survival, though this did not apply to responses observed in brain metastases.

As to why that might be the case, Lee noted that the metastases in the brain may have been smaller than those in other parts of the body and that the blood brain barrier could have filtered out ctDNA before it reached the blood.

The team concluded that though ctDNA could be useful for monitoring treatment efficacy in metastatic melanoma, it may not be helpful in detecting brain metastasis or monitoring whether the brain tumors respond to immune checkpoint therapy. This study has potentially important implications because up to half of melanoma patients exhibit brain metastases at some point in their treatment.

Chimeric cell-free DNA can track tumor recurrence in hepatocellular carcinoma

One third of patients with hepatocellular carcinoma (HCC) experience tumor recurrence within the first year following surgery. Detecting and tracking recurrent tumors is essential for physicians to implement therapeutic trials at the right time.

Most patients with HCC have been infected with hepatitis B virus (HBV) and harbor virus host (vh)-chimera DNA, the result of viral DNA integrating into HCC chromosomes. To determine whether vh-chimera DNA could serve as a more sensitive biomarker of HCC progression than currently available tests, Ya-Chun Wang, PhD, of TCM Biotech International Corporation, and his colleagues used ddPCR technology to quantify vh-chimera DNA in plasma samples in patients with HBV-related HCC before and after tumor removal surgery. The researchers detected and quantified vh-chimera DNA before surgery in 44 of 50 patients.

Of the patients whose plasma samples still contained vh-chimera DNA two months after surgery, 82 percent had a tumor recur in the following year. Furthermore, in all but two patients, the vh-chimera DNA matched that of the original clone, indicating that the majority of recurrences come from original HCC cells.

The authors note that the findings support vh-chimera DNA as a biomarker to complement existing ones in detecting the existence of HBV-HCC and in tracking tumor recurrence based on vh-chimera clonalities.

“The ddPCR assay provides an advantage for sensitive quantification of chimera DNA,” Wang said. “In our current practice, the target chimera DNA in blood can be detected as low as one to two copies per reaction.”

Please visit bio-rad.com/digitalPCR to learn more about Bio-Rad’s Droplet Digital PCR technology presented at ASCO.

Bio-Rad, ddPCR, and Droplet Digital PCR are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.2 billion in 2018. For more information, please visit www.bio-rad.com.

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Press Contact:
Bio-Rad Laboratories, Inc.
Lisa Jensen-Long
520-240-7904
Lisa_Jensen-Long@bio-rad.com

CG Life
Ken Li
312-997-2436
kli@cglife.com

Sign Up for Bio-Rad Updates!
Enter your email address below to receive your choice of the latest news, promotions, and more.
Get Help
New-Data-on-Circulat_1562803413 [x-forwarded-proto] = [http] [accept-language] = [en-US,en;q=0.5] [x-forwarded-port] = [80] [x-forwarded-for] = [34.229.113.106, 10.232.3.62] [accept] = [text/html,application/xhtml+xml,application/xml;q=0.9,*/*;q=0.8] [seourl] = [/en-us/life-science-research/news/new-data-circulating-tumor-dna-as-biomarker-for-detecting-cancer-progression-presented-at-2019-asco-annual-meeting] [x-amzn-trace-id] = [Root=1-5d3098f2-9ff614ec79be968e17fa0934] [x-forwarded-server] = [lsds-prod-s.br.aws-livesite.io] [x-forwarded-host] = [www.bio-rad.com] [x-query-string] = [ID=New-Data-on-Circulat_1562803413] [host] = [10.232.16.28:1776] [x-request-uri] = [/en-us/life-science-research/news/new-data-circulating-tumor-dna-as-biomarker-for-detecting-cancer-progression-presented-at-2019-asco-annual-meeting] [connection] = [Keep-Alive] [accept-encoding] = [gzip] [user-agent] = [CCBot/2.0 (https://commoncrawl.org/faq/)] Vertical/VerticalArticleDetail pageStyleKey life-science-research/news/new-data-circulating-tumor-dna-as-biomarker-for-detecting-cancer-progression-presented-at-2019-asco-annual-meeting LSR https://www.bio-rad-antibodies.com https://www.bio-rad.com 03/26/14 02:17 PM en_US true internet/generic 2019-07-09 16:59:23 /default/main/bio-rad/STAGING 1385504243813 US templatedata/internet/generic/data/en_US/GNL/page_generic_footer_b2c_1385505294_US.xml page_generic_footer_b2c /default/main/bio-rad/WORKAREA/default jc7v8okm 2017-10-27 13:13:40 true Done jc7v8okm templatedata/internet/generic/data/en_US/GNL/page_generic_footer_b2c_1385505294_US.xml GNL N /default/main/bio-rad en_US 11/27/23 02:18 PM 1561946660551 2019-07-09 16:59:23 /default/main/bio-rad/WORKAREA/default/templatedata/internet/generic/data/en_US/GNL/page_generic_footer_b2c_1385505294_US.xml footer 1 1385504243813 page_generic_footer_b2c <div class="col"> <h4>Support</h4> <ul> <li><a class="wtclass linkgeneration" href="_brcDomain/_locale/life-science-research/support?ID=1140">Life Science Support</a></li> <li><a class="wtclass linkgeneration" href="_acdDomain/technical-support.html">Antibodies Support</a></li> <li><a class="wtclass linkgeneration" href="_brcDomain/_locale/life-science-research/purchase-service-programs/expert-care-service?ID=1383780912356">Expert Care Service</a></li> <li><a class="wtclass linkgeneration" href="_brcDomain/contact">Contact Us</a></li> </ul> </div> <div class="col"> <h4>Documents</h4> <ul> <li><a class="wtclass linkgeneration" href="_brcDomain/_locale/literature-library">Literature Library</a></li> <li><a class="wtclass linkgeneration" href="_brcDomain/_locale/life-science-research/support/certificate-of-analysis">Certificate of Analysis</a></li> <li><a class="wtclass" href="https://myeinserts.qcnet.com/" target="_blank" rel="noopener noreferrer">QC Inserts</a></li> <li><a class="wtclass linkgeneration" href="_acdDomain/iso-9001-quality-assurance-management.html">Quality Certification</a></li> </ul> </div> <div class="col"> <h4>Ordering</h4> <ul> <li><a class="wtclass linkgeneration" href="_brcDomain/_locale/my-bio-rad">Quick Order</a></li> <li><a id="footer_orderLink" class="orderhistoryLink wtclass" href="javascript:void(0);">Order History</a></li> <li><a class="wtclass" id="footer_quoteLink" href="javascript:void(0);">Quote History</a></li> <li><a class="wtclass linkgeneration" href="_brcDomain/_locale/my-bio-rad">My Bio-Rad</a></li> <li><a class="wtclass linkgeneration" href="_brcDomain/_locale/life-science-research/purchase-service-programs/supply-center-program?ID=1383773882551">Supply Centers</a></li> </ul> </div> <div class="col"> <h4>Our Products</h4> <ul> <li><a class="wtclass linkgeneration" href="_brcDomain/_locale/life-science-research?ID=1100">Life Science Research</a></li> <li><a class="wtclass linkgeneration" href="_acdDomain/">Antibodies</a></li> <li><a class="wtclass linkgeneration" href="_brcDomain/_locale/clinical-diagnostics?ID=1200">Clinical Diagnostics</a></li> <li><a class="wtclass linkgeneration" href="_brcDomain/_locale/spectroscopy?ID=1300">Spectroscopy</a></li> <li><a class="wtclass linkgeneration" href="_brcDomain/_locale/process-separations?ID=1400">Process Separations</a></li> <li><a class="wtclass linkgeneration" href="_brcDomain/_locale/food-science?ID=1475">Food Science</a></li> <li><a class="wtclass linkgeneration" href="_brcDomain/_locale/education?ID=1450">Life Science Education</a></li> </ul> </div> <div class="col"> <h4>Company</h4> <ul> <li><a class="wtclass linkgeneration" href="_brcDomain/_locale/corporate/about-bio-rad?ID=1003">About Bio-Rad</a></li> <li><a class="wtclass linkgeneration" href="_brcDomain/_locale/corporate/careers?ID=1004">Careers</a></li> <li><a class="wtclass linkgeneration" href="_brcDomain/_locale/corporate/investor-relations?ID=1007">Investor Relations</a></li> <li><a class="wtclass linkgeneration" href="_brcDomain/_locale/corporate/newsroom?ID=1006">Newsroom</a></li> <li><a class="wtclass linkgeneration" href="_acdDomain/blog/">Blog</a></li> <li><a class="wtclass" target="_blank" href="https://www.bioradiations.com" rel="noopener noreferrer">Bioradiations</a></li> <li> <div class="social"> <ul> <li><a class="no-target-style brconly wtclass" href="https://www.linkedin.com/company/bio-rad?trk=top_nav_home" target="_blank" rel="noopener noreferrer"><img src="https://www.bio-rad.com/webroot/web/images/general/icons/linkedin_round_40x40.png" alt="Bio-Rad LinkedIn" width="20" height="20" /></a> <a class="no-target-style bracd wtclass" style="display: none;" href="https://www.linkedin.com/company/bio-rad-antibodies" target="_blank" rel="noopener noreferrer"><img src="https://www.bio-rad.com/webroot/web/images/general/icons/linkedin_round_40x40.png" alt="Bio-Rad Antibodies LinkedIn" width="20" height="20" /></a></li> <li><a class="no-target-style brconly wtclass" href="https://www.youtube.com/user/BioRadLifeScience" target="_blank" rel="noopener noreferrer"><img src="https://www.bio-rad.com/webroot/web/images/general/icons/youtube-icon-rnd-40x40.png" alt="Bio-Rad YouTube" width="20" height="20" /></a> <a class="no-target-style bracd wtclass" style="display: none;" href="https://www.youtube.com/playlist?list=PLrAEgIY86I6w1jajKp3O9RQJEvJZ2ux0I" target="_blank" rel="noopener noreferrer"><img src="https://www.bio-rad.com/webroot/web/images/general/icons/youtube-icon-rnd-40x40.png" alt="Bio-Rad Antibodies YouTube" width="20" height="20" /></a></li> <li><a class="no-target-style brconly wtclass" href="https://twitter.com/BioRadLifeSci" target="_blank" rel="noopener noreferrer"><img src="https://www.bio-rad.com/webroot/web/images/general/icons/twitter_round_40x40.png" alt="Bio-Rad Twitter" width="20" height="20" /></a> <a class="no-target-style bracd wtclass" style="display: none;" href="https://twitter.com/BioRadAbs" target="_blank" rel="noopener noreferrer"><img src="https://www.bio-rad.com/webroot/web/images/general/icons/twitter_round_40x40.png" alt="Bio-Rad Antibodies Twitter" width="20" height="20" /></a></li> <li><a class="no-target-style brconly wtclass" href="https://www.facebook.com/biorad/" target="_blank" rel="noopener noreferrer"><img src="https://www.bio-rad.com/webroot/web/images/general/icons/facebook-icon-rnd-40x40.png" alt="Bio-Rad Facebook" width="20" height="20" /></a> <a class="no-target-style bracd wtclass" style="display: none;" href="https://www.facebook.com/BioRadAntibodies" target="_blank" rel="noopener noreferrer"><img src="https://www.bio-rad.com/webroot/web/images/general/icons/facebook-icon-rnd-40x40.png" alt="Bio-Rad Antibodies Facebook" width="20" height="20" /></a></li> <li><a class="no-target-style wtclass" href="https://www.instagram.com/bioradlabs/" target="_blank" rel="noopener noreferrer"><img src="https://www.bio-rad.com/webroot/web/images/general/icons/instagram-icon-rnd-40x40.png" alt="Bio-Rad Instagram" width="20" height="20" /></a></li> <li><a class="no-target-style wtclass" href="https://uk.pinterest.com/BioRadAbs/" target="_blank" rel="noopener noreferrer"><img src="https://www.bio-rad.com/webroot/web/images/general/icons/pinterest40x40.png" alt="Bio-Rad Pinterest" width="20" height="20" /></a></li> </ul> </div> </li> </ul> </div> /webroot/web/html footer_page_b2c_en_US.html /webroot/web/html/footer_page_b2c_en_US.html Karen Moss Footer page Footer 03/26/14 02:17 PM 11/27/23 02:18 PM US en GNL /GNL N 0 en-us Home <script type="text/javascript">$(document).ready(function() { var region = $("#headlangID .lang strong").html(); $(".footer-nav > a:nth-child(3)").after(" | <a href='https://www.bio-rad.com/webroot/web/html/featured/en/web-accessibility.html' id='regionlink'>Web Accessibility</a>");});</script>Trademarks Site Terms Terms & Conditions Imprint EU Recycle Program Privacy Change Cookie Setting <script type="text/javascript">$(document).ready(function () {$(".links2").append('<style>.social-links-br {float: left;margin-right: 10px;}.social-links-br img {width: 20px;height: 20px;margin-right: 5px}</style><div class="social-links-br"><a class="no-target-style" href="https://www.linkedin.com/company/bio-rad?trk=top_nav_home" target="_blank"><img src="/webroot/web/images/general/icons/linkedin_round_40x40.png" alt="Bio-Rad LinkedIn"></a><a class="no-target-style" href="https://www.youtube.com/user/BioRadLifeScience" target="_blank"><img src="/webroot/web/images/general/icons/youtube-icon-rnd-40x40.png" alt="Bio-Rad YouTube"></a><a class="no-target-style" href="https://twitter.com/BioRadLifeSci" target="_blank"><img src="/webroot/web/images/general/icons/twitter_round_40x40.png" alt="Bio-Rad Twitter"></a><a class="no-target-style" href="https://www.facebook.com/biorad/" target="_blank"><img src="/webroot/web/images/general/icons/facebook-icon-rnd-40x40.png" alt="Bio-Rad Facebook"></a><a class="no-target-style" href="https://www.instagram.com/bioradlabs/" target="_blank"><img src="/webroot/web/images/general/icons/instagram-icon-rnd-40x40.png" alt="Bio-Rad Instagram"></a></div>');});</script>Copyright &copy; {0} Bio-Rad Laboratories, Inc. All rights reserved. This page was last edited on {0} true True GTM-MJ2DN2S us US en LSR life-science-research life-science-research /prd/en/US/direct/biorad?ts=1&cmd=OrdersWorkspaceDisplay /prd/en/US/direct/biorad?ts=1&cmd=QuotesWorkspaceDisplay /prd/en/US/direct/biorad?ts=1&cmd=InvoiceWorkspaceDisplay&_Tab=Invoice false false true false true true 1040988879 LHsYCOu_wQMQz_Ww8AM window.google_tag_params true 272-THL-329 username CartID_ WT_FPC <script type="text/javascript">$.ajax({url: document.location.protocol + '//munchkin.marketo.net/munchkin.js',dataType: 'script',cache: true,success: function() {Munchkin.init('044-CBN-599');}});</script> <script type="text/javascript" src="https://www.bio-rad.com/evportal/framework/skins/evolution/js/proxyMunchkin.js"></script> 2019 {"country":"us","b2b_punch_out_mode":"","pageType":"other","user_id":"","visitorLoginState":false,"visitorType":"","sessionType":"B2C","language":"en","vertical":"LSR","b2b_org_id":""}